Transition Metal-based Anticancer Drugs Targeting Nucleic Acids: A Tandem Mass Spectrometric Investigation

Authors

  • Rahel P. Eberle Department of Chemistry and Biochemistry, University of Bern, Freiestrasse 3, CH-3012 Bern, Switzerland
  • Yvonne Hari Department of Chemistry and Biochemistry, University of Bern, Freiestrasse 3, CH-3012 Bern, Switzerland
  • Stefan Schürch Department of Chemistry and Biochemistry, University of Bern, Freiestrasse 3, CH-3012 Bern, Switzerland. stefan.schuerch@dcb.unibe.ch

DOI:

https://doi.org/10.2533/chimia.2017.120

Keywords:

Anticancer drugs, Cisplatin, Metallocenes, Nucleic acids, Tandem mass spectrometry

Abstract

The search for effective drugs against cisplatin-resistant tumors resulted in a large number of organometallic compounds that are evaluated for their antiproliferative activity. Among the most promising candidates are bent metallocenes based on various transition metal ions and ligands. The elucidation of structural features and the characterization of the interaction of a drug candidate with its target require accurate and sensitive analytical tools. Tandem mass spectrometry is applied to the investigation of the adduct sites and binding patterns of metallodrugs bound to single-stranded oligonucleotides and higher-order nucleic acids. Results reveal the binding specificities of the different metallodrugs and demonstrate the influence they exert on the dissociation pathways of the adducts in the gas-phase.

Downloads

Published

2017-03-29

How to Cite